Expert Answers in HER2+ Gastroesophageal Adenocarcinoma – with Dr. Yelena Janjigian
The treatment landscape for HER2+ gastroesophageal adenocarcinoma (GEA) has changed dramatically in recent years, creating new hope for patients and their families. Hear a perspective from gastrointestinal medical oncologist Dr. Yelena Janjigian.
“What keeps me hopeful and what continuously energizes me and brings me back to clinic is this constantly evolving landscape.”
Finding Hope Through Progress in HER2+ GEA
As part of our Expert Answers in HER2+ Gastroesophageal Adenocarcinoma series, leading specialists share practical insights to help patients and caregivers better understand the disease and navigate conversations with their healthcare team.
In this installment, Dr. Yelena Janjigian, Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center, discusses:
- Frequent questions after a diagnosis of HER2+ GEA
- How biomarker testing helps create a roadmap for treatment
- How advances in HER2-targeted therapies are transforming outcomes
Explore more Expert Answers in HER2+ Gastroesophageal Adenocarcinoma:
- Manish Shah, MD, Gastrointestinal Oncologist at NewYork-Presbyterian/Weill Cornell Medical Center
- Jaffer A. Ajani, MD, Gastrointestinal Oncologist at MD Anderson Cancer Center
